Introduction
Although brain tumor etiology remains largely unknown (1) (2) (3) , there are consistent reports of inverse associations between risk of adult glioma and personal history of allergy (4) (5) (6) (7) (8) (9) (10) and, to a lesser extent, autoimmune disease (4, 6, 7) . It is unlikely that all reported associations are subject to similar bias or due to chance; however, it remains unclear whether changes in cellular/humoral immunity and cytokine pattern accompanying allergy or autoimmune disease are protective for glioma directly or through another unidentified factor. Interestingly, polymorphisms in IL4RA and IL13 genes previously associated with decreased and increased risk of asthma, respectively, were found to have opposite associations with glioma in one study (11) . In another study, however, polymorphisms in IL4, IL4R and IL13 genes were unassociated with risk of glioma individually, yet certain IL4R and IL13 haplotypes demonstrated suggestive associations (12) . Our objective was to evaluate and extend the evidence that single-nucleotide polymorphisms (SNPs) in cytokine genes are related to risk of adult glioma using data from two large, independent case-control studies. Here, we report associations with 11 SNPs in seven cytokine genes.
Materials and methods

Study population and setting
Details of the studies conducted by the National Cancer Institute (NCI) and the National Institute for Occupational Safety and Health (NIOSH) were described previously (13, 14) and are summarized in Table I . Briefly, the NCI study was conducted between June 1994 and August 1998 at Brigham and Women's Hospital in Boston, MA; St Joseph's Hospital and Medical Center in Phoenix, AZ and Western Pennsylvania Hospital in Pittsburgh, PA. Eligible cases were patients newly diagnosed with histologically confirmed intracranial glioma or neuroepitheliomatous tumors (N 5 489; International Classification of Diseases for Oncology, second edition codes 9380-9473 and 9490-9506). Cases had to be at least 18 years old and reside within 50 miles of the hospital at the time of diagnosis (or within Arizona for the Phoenix hospital) and understand English or Spanish. Of the potentially eligible cases invited to participate in the study, 90% (N 5 489) agreed. Controls were patients admitted to same hospitals for a variety of non-malignant conditions. The most common reasons for hospital admission among controls were injuries and poisoning [N 5 197; ICD-9 (International Classification of Diseases, Ninth Revision) 800-999, V01-V82, E800-E999] and diseases of the circulatory (N 5 179; ICD-9 390-459), musculoskeletal (N 5 172; ICD-9 710-739), digestive (N 5 92, ICD-9 520-579) and nervous systems (N 5 58; ICD-9 320-389). Controls were frequency matched (1:1) to a total case series (glioma, meningioma and acoustic neuroma) by hospital, age (in 10-year strata), sex, race or ethnicity, and distance of residence from hospital. Of the potentially eligible controls contacted, 86% (N 5 799) participated.
The NIOSH eligible cases were patients, 18-80 years old, diagnosed between January 1995 and January 1997 with new, histologically confirmed intracranial gliomas (International Classification of Diseases for Oncology, second edition codes 9380-9473) in the participating medical facilities and neurosurgeon offices in four upper Midwestern states (in counties where the largest population center had , 250 000 residents) (14) . Of the potentially eligible cases invited to participate in the study, 92% (N 5 798) agreed. Population controls were individuals without glioma randomly selected from 10-year age-sex specific strata of the state driver's license or non-driver identification records (for those between 18 and 64 years of age) or from the Health Care Financing Administration Medicare records (for those between 65 and 80 years). Controls were frequency matched to cases (1.5:1) by state of residence, sex and age. Of the potentially eligible controls contacted, 70% (N 5 1175) participated.
Both studies were reviewed and approved by the respective institutional review boards, and all participants signed an informed consent upon enrollment.
Laboratory methods
Blood sample collection and DNA extraction In the NCI study, 431 cases (88%) and 611 controls (76%) provided blood samples, whereas in the NIOSH study 325 cases (41% of all participating cases or 71% of 458 alive at the time of interview) and 579 controls (73% of 793 asked) did so.
DNA was extracted from peripheral white blood cells of blood samples collected in the NCI study using a phenol-chloroform method described previously (15) . DNA was extracted from whole-blood samples in the NIOSH study using a sodium perchlorate-chloroform method (16).
Genotyping Genotyping for both studies was performed by the NCI Core Genotyping Facility (Advanced Technology Corporation, Gaithersburg, MD) using optimized singleplex assays (17). The selection of a portion of common genetic variants was coordinated between the two studies to increase statistical power, provide protection against false-positive findings and reduce the probability of false-negative findings. The genes were chosen based on the most consistent evidence from association studies with allergy, autoimmune disease, cancer or neurologic diseases at the time of selection, with those SNPs known to have functional consequences in polymorphism or having assays available at Core Genotyping Facility given preference (Table II) . Here, we report only on SNPs that were genotyped in both studies.
We observed no significant deviation from Hardy-Weinberg equilibrium for any SNP, and concordance rates for the quality control replicate and duplicate samples were at least 93 and 98%, respectively.
Statistical analysis
Data from each study were first analyzed separately. We used unconditional multivariate logistic regression models [PROC LOGISTIC, SAS 8.2 (18) ] to estimate odds ratios associated with each SNP (using the homozygous wildtype genotype as referent) and to compute 95% confidence intervals adjusting for study-specific matching factors. For each SNP, we conducted a score test of linear trend using a three-level ordinal variable. As there was no evidence of heterogeneity in linear trends between the two studies, we combined data and estimated pooled odds ratios using fixed effects models (19) . All analyses were restricted to non-Hispanic whites.
We assessed robustness of findings using the Benjamini-Hochberg approach to control for false discovery rate (FDR) (20) , defined as the expected ratio of Abrreviations: SNP, single-nucleotide polymorphism; NCI, National Cancer Institute; NIOSH, National Institute for Occupational Safety and Health.
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erroneous rejections of the null hypothesis to the total number of rejected hypotheses. We applied the FDR method to a set of 11 tests for trend (as this allows for the fewest number of comparisons) at the a 5 0.05 level.
To decrease phenotypic heterogeneity of the glioma case series and to compare our findings with those of Schwartzbaum et al. (11) , all analyses were repeated limited to glioblastoma cases. 
Results
The IL4 (rs2243248, À1098T.G) polymorphism in the NCI study was significantly associated with overall risk of glioma. The associations with IL4 (rs2243248, À1098T.G) and IL6 (rs1800795, À174G.C) polymorphisms were compatible between the two studies (Table III) , and the pooled odds ratios with GT and GG genotypes were 1.44 and 3.90 (P trend 5 0.006), and with CG and CC genotypes were 0.98 and 0.70 (P trend 5 0.04), respectively. These associations were attenuated after controlling for the FDR at the conservative level of 0.05 [P trend with IL4 (rs2243248, À1098T.G) 5 0.07 and P trend with IL6 (rs1800795, À174G.C) 5 0.22]. When limited to glioblastoma, the associations with IL4 (rs2243248, À1098T.G) and IL6 (rs1800795, À174G.C) polymorphisms were largely similar to the overall findings. The complete results for all SNPs for both studies are provided online (supplementary Table 1 for NCI results and supplementary Table 2 for NIOSH results are available at Carcinogenesis Online).
Discussion
Previous studies, including our own, have reported a consistent inverse relationship between adult glioma and history of allergy (4-10) and, to a lesser extent, autoimmune disease (4,6,7). Using six SNPs as biomarkers of susceptibility to asthma, a study with 111 cases and 422 controls reported significant associations with IL4RA (rs1801275) and IL13 (rs1800925) polymorphisms and glioblastoma (11) . In a recent study (12) , association with IL4RA (rs1801275) was not confirmed, but association with IL13 (rs1800925) appeared to be consistent with that by Schwartzbaum et al. (11) , although it did not reach statistical significance. Similarly, we did not confirm the IL4RA (rs1801275) association, and the associations with IL4 (rs2243250, rs2070874) polymorphisms were null. We found that common IL6 (rs1800795, À174G.C) and rare IL4 (rs2243248, À1098T.G) polymorphisms, previously not evaluated in relation to risk of adult glioma, were associated with it in our pooled analyses. While attenuated after controlling for FDR, these associations are noteworthy and warrant replication in larger, more powerful studies and pooled efforts. Although the IL4 promoter variant (rs224350, À588C.T), in strong linkage disequilibrium (D# 5 1.0) with IL4 (rs2243248, À1098T.G) in our population, was previously found to be associated with increased transcriptional activity of IL4 in vitro (21) and elevated risk of asthma (22,23), we do not yet know the functional relevance of the single-base substitution in the promoter of IL4 (rs2243248, À1098T.G) (17) or its relationship with allergy or asthma. In at least one study, the G allele of the IL4 (rs2243248, À1098T.G) polymorphism was associated with decreased risk of juvenile idiopathic ar- Table III . Associations between IL4 (rs2243248, À1098T.G) and IL6 (rs1800795, À174G.C) polymorphisms and risk of adult glioma in non-Hispanic whites: pooled analysis of hospital-based case-control study conducted by the NCI and population-based case-control study conducted by the NIOSH
Study
Genotype Controls All glioma Glioblastoma ORs adjusted for study and sex, age and residence within each study.
SNPs in cytokine genes and risk of adult glioma thritis (24) and, thus, an opposite association with IL4 (rs2243248, À1098T.G) for glioma observed in our study appears to be consistent with the expectation based on epidemiologic studies (4, 6, 7) . The IL6 (rs1800795, À174G.C) polymorphism in the promoter region has been associated with decreased IL6 expression and lower plasma levels of circulating IL-6 (25, 26) as well as type-1 diabetes mellitus (27, 28) ; however, the latter associations went in different directions in the two studies. Although it is conceivable that IL4 and IL6 promoter polymorphisms may be related to the altered expression of the respective cytokines, these variants could alternatively be in linkage disequilibrium with other variants not yet evaluated. Mirroring our findings for glioma, IL4 (rs2243248, À1098T.G) and IL6 (rs1800795, À174G.C) polymorphisms recently have been associated with increased (29, 30) and decreased (29, 31) risk of several lymphoma subtypes, respectively. Therefore, these polymorphisms may influence susceptibility to several types of cancer, strengthening the possibility that the observed associations in our study are not due to chance. The complex relationship between glioma and allergy/autoimmune disease and cytokine gene polymorphisms remains unclear. However, it has been suggested that the effects of the IL13 polymorphisms and IgE on glioma risk may be statistically independent (12) . Such an independent effect of cytokines or their polymorphisms would be consistent with the emerging role of cytokines as important regulators of a variety of physiological and pathological processes in the central nervous system (32, 33) and key messengers in bidirectional communication between neural and immune cells (34) .
We had adequate statistical power to detect strong to modest main effects of the common genetic polymorphisms. The SNPs for candidate cytokine genes were carefully selected based on prior evidence and potential relevance to glioma, increasing the prior probability of true association. In the analyses, we controlled for FDR. We believe that accurate genotyping according to a standardized approach in both studies minimized misclassification, further enhancing our ability to detect modest effects.
Although among the largest glioma studies to date, our study had limited statistical power to detect modest to weak associations. If glioma survival was associated with the SNPs under consideration, this could introduce survival bias given that blood samples were available for 41% of all NIOSH cases compared with 88% of NCI cases. However, findings from the two studies were consistent, both for all gliomas combined and for glioblastoma, where the potential for such survival bias is highest. We evaluated only one to three SNPs per gene and, therefore, our conclusions pertain to specific genotypes and not the entire gene or region. Furthermore, additional regulation at the level of transcription or translation, or complex interactions among the cytokines, would not be captured in our results.
In summary, using data from two large, independent case-control studies, we found suggestive associations between glioma and IL4 (rs2243248, À1098T.G) and IL6 (rs1800795, À174G.C) polymorphisms. Further studies with sufficient power focusing on dense genotyping and haplotype estimation of the cytokine genes are warranted. Our findings underscore the importance of pooled analyses in genetic association studies and, if confirmed, could imply that genetic polymorphisms in cytokine genes are important susceptibility factors for glioma.
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